Lung cancer in women: An overview with special focus on Spanish women

Clinical and Translational Oncology

Volumn 16, Issue 6, 2014, Pages 517-528

  Remon, J ^a   Molina Montes, E ^b,c   Majem, M ^d   Lianes, P ^a   Isla, D ^e   Garrido, P ^f   Felip, E ^g   Vinolas N ^h   De Castro, J ⁱ   Artal, A ^j   Sanchez M J ^b,c  

^a HOSPITAL DE MATARÓ   (Spain)

^b ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^j HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

more..

Author keywords

Epidemiology; Lung cancer; Outcome; Spain; Women

Indexed keywords

CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SUSCEPTIBILITY; EUROPE; FEMALE; GENE MUTATION; HISTOLOGY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; PERCEPTION; PREDICTION; PREVALENCE; REVIEW; SEX DIFFERENCE; SMOKING; SPAIN; CARCINOMA, NON-SMALL-CELL LUNG; EPIDEMIOLOGY; INCIDENCE; LUNG NEOPLASMS; MALE;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; SPAIN;

EID: 84901641206     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-013-1137-7     Document Type: Review

References (101)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;12:2893-917.
3. Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol. 2008;3:819-31.
4. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374-403.
5. Steliarova-Foucher E, O'callaghan M, Ferlay J, Massuyer E, Forman D, Comber H et al. European cancer observatory: cancer incidence, mortality, prevalence and survival in Europe. Version 1.0 (September 2012) European Network of Cancer Registries, International Agency for Research on Cancer. http://eco.iarc.fr. Accessed on 23/2/2013.
6. Sanchez MJ, Payer T, De Angelis R, Larrannaga N, Capocaccia R, Martínez C, et al. Cancer incidence and mortality in Spain: estimates and projections for the period 1981-2012. Ann Oncol. 2010;21(Suppl 3):iii30-6.
7. Izarzugaza MI, Ardanaz E, Chirlaque MD, Font C, Ameijide A, Linares C, et al. Tobacco-related tumours of the lung, bladder and larynx: changes in Spain. Ann Oncol. 2010;21(Suppl 3):iii52-60.
8. La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, et al. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol. 2010;21:1323-60.
9. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2013. Ann Oncol. 2013;24:792-800.
10. Bosetti C, Malvezzi M, Rosso T, Bertuccio P, Gallus S, Chatenoud L, et al. Lung cancer mortality in European women: trends and predictions. Lung Cancer. 2012;78:171-8.
11. Bray FI, Weiderpass E. Lung cancer mortality trends in 36 European countries: secular trends and birth cohort patterns by sex and region 1970-2007. Int J Cancer. 2010;126:1454-66.
12. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
13. Papadopoulous A, Guida F, Cénée S, Cyr D, Schmaus A, Radoï L, et al. Cigarette smoking and lung cancer in women: results of the French ICARE case-control study. Lung Cancer. 2011;74:369-77.
14. Agudo A, Bonet C, Travier N, González A, Vineis P, Bueno-de-Mesquita HB, et al. Impact of cigarette smoking on cancer risk in the European prospective investigation into cancer and nutrition study. J Clin Oncol. 2012;30:4550-7.
15. Lopez AD, Collishaw NE, Piha T. A descriptive model of cigarette epidemic in developed countries. Tob Control. 1994;3:242-7.
16. Health at Glance: Europe 2012. Smoking among adults. http://www. oecdilibrary.org/. Accessed on 14.07.13.
17. http://ec.europa.eu/public-opinion/archives/ebs/ebs-385-en.pdf. Accessed on 29.07.13.
18. Boniol M, Autier P. Prevalence of main cancer lifestyle risk factors in Europe in 2000. Eur J Cancer. 2010;46:2534-44.
19. Fernandez E, Schiaffino A, Borràs JM, Shafey O, Villabí JR, La Vecchia C. Prevalence of cigarette smoking by birth cohort among males and females in Spain 1910-1990. Eur J Cancer Prev. 2003;12:57-62. (Pubitemid 36233023)
20. Khuder SA, Mutgi AB. Effect of smoking cessation on major histologic types of lung cancer. Chest. 2001;120:1577-83. (Pubitemid 33078475)
21. Martinez-Sanchez JM, Fernandez E, Fu M, Gallus S, Martínez C, Sureda X, et al. Smoking behaviour, involuntary smoking, attitudes towards smoke-free legislations, and tobacco control activities in the European Union. PLoS One. 2010;5(11):e13881.
22. Schaap MM, Kunst AE, Leinsalu M, Regidor E, Ekholm O, Dzurova D, et al. Effect of nationwide tobacco control policies on smoking cessation in high and low educated groups in 18 European countries. Tob Control. 2008;17:248-55.
23. Brown A, Mcneill A, Mons U, Guignard R. Do smokers in Europe think all cigarettes are equally harmful? Eur J Public Health. 2012;22(Suppl 1):35-40.
24. Li Q, Dresler C, Heck JE, Allwright S, Haglund M, Sanchez S, et al. Knowledge and beliefs about smoking and cancer among women in five European countries. Cancer Epidemiol Biomarkers Prev. 2010;19:2811-20.
25. Dresler C, Wei M, Heck JE, Allwright S, Haglund M, Sanchez S, et al. Attitudes of women from five European countries regarding tobacco control policies. Scand J Public Health. 2013;41:126-33.
26. Majem M, Artal A, De Castro J, Felip E, Isla D, Garrido P, et al. Population survey to assess the knowledge of smoking habit and its consequences on women in Spain. J Clin Oncol. 2012;30(suppl; abstract e12000).
27. http://www.msc.es/estadEstudios/estadisticas/encuestaNacional/ encuesta2011.htm. Accessed on 23/05/2013.
28. Banegas JR, Diez-Gañán L, Buñuelos-Marco B, Gonzalez-Enriquez J, Villar-Alvarez F, Martin-Moreno JM, et al. Smoking-attributable deaths in Spain 2006. Med Clin. 2011;136:97-102.
29. Warren CW, Jones NR, Eriksen MP, Asma S. Patterns of global tobacco use in young people and implications for future chronic disease burden in adults. Lancet. 2006;367:749-53. (Pubitemid 43326293)
30. http://www.espad.org/Uploads/ESPAD-reports/2011/. Accessed on 15/07/2013.
31. Mendoza R, López P, Sagrera MR. Diferencias de género en la evolución del tabaquismo adolescente en España (1986-2002). Adicciones. 2007;19:273-88.
32. Hublet A, Schmid H, Clays E, Godeau E, Gabbhainn SN, Joossens L, et al. Association between tobacco control policies and smoking behaviour among adolescents in 29 European countries. Addiction. 2009;104:1918-26.
33. Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer. 2001;31:139-48. (Pubitemid 32107010)
34. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner MJ, editors. SEER survival monograph: cancer survival among adults: US SEER program, 1988-2001: patient and tumor characteristics. NIH Publications No 07-6215. Bethesda: National Cancer Institute; 2007. http://seer.cancer.gov/publications/survival/. Accessed on 23/07/2013.
35. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst. 1996;88:183-92. (Pubitemid 26065830)
36. Hsu LH, Chu NM, Liu CC, Tsai SY, You DL, Ko JS, et al. Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor? Lung Cancer. 2009;66:262-7.
37. Ferguson MK, Skosey C, Hoffman PC, Golomb HM. Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol. 1990;8:1402-7. (Pubitemid 20252313)
38. De Perrot M, Licker M, Bouchardy C, Usel M, Robert J, Spiliopoulos A. Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg. 2000;119:21-6. (Pubitemid 30046309)
39. Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in women: analysis of the national surveillance, epidemiology, and end results database. Chest. 2005;127:768-77. (Pubitemid 40775504)
40. Minami H, Yoshimura M, Miyamoto Y, Matsuoka H, Tsubota N. Lung cancer in women: sex-associated differences in survival of patients undergoing resection for lung cancer. Chest. 2000;118:1603-9. (Pubitemid 32001783)
41. Visbal AL, Williams BA, Nichols FC 3rd, Marks RS, Jett JR, Aubry MC, et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg. 2004;78:209-15. (Pubitemid 38842439)
42. Sagerup CM, Smastuen M, Johannesen TB, Helland A, Brustugun OT. Sex-specific trends in lung cancer incidence and survival: a population study of 40,118 cases. Thorax. 2001;66:301-7.
43. Dresler C. The changing epidemic of lung cancer and occupational and environmental risk factors. Thorac Surg Clin. 2012;23:113-22.
44. Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25:5570-7.
45. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol. 2002;13:1087-93.
46. Salmeron D, Chirlaque MD, Izarzugaza MI, x MJ, Marcos-Gragera R, Ardanaz E, et al. Lung cancer prognosis in Spain: the role of histology, age and sex. Respir Med. 2012;106:1301-8.
47. Parente I, Abal J, García MJ. Cáncer de pulmón en mujeres, comparativo con hombres: análisis de los casos diagnosticados en el Complexo Hospitalario de Ourense entre 1999-2006. Archivos de Bronconeumología. 2011;47:61-5.
48. Isla D, Provencio M, Majem M, Felip E, Garrido P, Viñolas N, et al. Never-smoking women with lung cancer from the Spanish WORLD07 database. J Clin Oncol. 2012;(Suppl 30; abstract 1531).
49. International Early Lung Cancer Action Program I, Henschke CI, Yip R, Miettinen OS. Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA. 2006;296:180-4.
50. Powell HA, Iyen-Omofoman B, Hubbard RB, Baldwin DR, Tata JL. The association between smoking quantity and lung cancer in men and women. Chest. 2013;143:123-9.
51. Higashi E, Fukami T, Itoh M, Kyo S, Inoue E, Yokoi T, et al. Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos. 2007;35:1935-41. (Pubitemid 47481589)
52. Xu W, Zhou Y, Hang X, Shen D. Current evidence on the relationship between CYP1B1 polymorphisms and lung cancer risk: a meta-analysis. Mol Biol Rep. 2012;39:2821-9.
53. Dresler CM, Fratelli C, Babb J, Everley L, Evans AA, Clapper ML. Gender differences in genetic susceptibility for lung cancer. Lung Cancer. 2000;30:153-60. (Pubitemid 32007871)
54. Cote ML, Yoo W, Wenzlaff AS, Prysak GM, Santer SK, Claeys GB, et al. Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women. Carcinogenesis. 2009;30:626-35.
55. Shriver SP, Bourdeau HA, Gubish CT, Tirpak DL, Davis AL, Luketich JD, et al. Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J Natl Cancer Inst. 2000;92:24-33. (Pubitemid 30082225)
56. Freedman ND, Leitzmann MF, Hollenbeck AR, Schatzkin A, Abnet CC. Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol. 2008;9:649-56.
57. De Matteis S, Consonni D, Pesatori AC, Bergen AW, Bertazzi PA, Caporaso NE, et al. Are women who smoke at higher risk for lung cancer than men who smoke? Am J Epidemiol. 2013;177:601-12.
58. Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ. Lung cancer in never smokers - a review. Eur J Cancer. 2012;48:1299-311.
59. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers - a different disease. Nat Rev Cancer. 2007;7:778-90. (Pubitemid 47463669)
60. Thun MJ, Hannan LM, Adams-Campbell LL, Boffetta P, Buring JE, Feskanich D, et al. Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med. 2008;5(9):e185.
61. Wakelee HA, Chang ET, Gómez SL, Keegan TH, Feskanich D, Clarke CA, et al. Lung cancer incidence in never smokers. J Clin Oncol. 2007;25:472-8. (Pubitemid 350002951)
62. Thun MJ, Henley SJ, Burns D, Jemal A, Shanks TG, Calle EE. Lung cancer death rate in lifelong nonsmokers. J Natl Cancer Inst. 2006;98:691-9. (Pubitemid 43832505)
63. Rouquette I, Lauwers-Cances V, Allera C, Brouchet L, Milia J, Nicaise Y, et al. Characteristics of lung cancer in women: importance of hormonal and growth factors. Lung Cancer. 2012;76:280-5.
64. Brinton LA, Gierach GL, Andaya A, Park Y, Schatzkin A, Hollenbeck AR, et al. Reproductive and hormonal factors and lung cancer risk in the NIH-AARP Diet and Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2011;20:900-11.
65. Pesatori AC, Carugno M, Consonni D, Caporaso NE, Wacholder S, Tucker M, et al. Reproductive and hormonal factors and the risk of lung cancer: the EAGLE study. Int J Cancer. 2013;132:2630-9.
66. Zhang Y, Yin Z, Shen L, Wan Y, Zhou B. Menstrual factors, reproductive factors and lung cancer risk: a meta-analysis. Zhongguo Fei Ai Za Zhi. 2012;15:701-19.
67. Greiser CM, Greiser EM, Doren M. Menopausal hormone therapy and risk of lung cancer: systematic review and meta-analysis. Maturitas. 2010;65:198-204.
68. Oh SW, Myung SK, Park JY, Lym YL, Ju W. Hormone therapy and risk of lung cancer: a meta-analysis. J Womens Health. 2010;19:279-88.
69. Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, Manson JE, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post hoc analysis of a randomised controlled trial. Lancet. 2009;374:1243-51.
70. Chlebowski RT, Anderson GL, Manson JE, Schwartz AG, Wakelee H, Gass M, et al. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J Natl Cancer Inst. 2010;102:1413-21.
71. Bouchardy C, Benhamou S, Schaffar R, Verkooijen HM, Floretta G, Schubert H, et al. Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer. 2011;117:1288-95.
72. Cote ML, Liu M, Bonassi S, Neri N, Schwartz AG, Christiani DC, et al. Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. Eur J Cancer. 2012;48:1957-68.
73. Klein F, Amin-Kotb WF, Petersen I. Incidence of human papilloma virus in lung cancer. Lung Cancer. 2009;65:13-8.
74. Lee JY, Jeon I, Lee JM, Yoon JM, Park SM. Diabetes mellitus as an independent risk factor for lung cancer: a meta-analysis of observational studies. Eur J Cancer. 2013;49:2411-23.
75. Johnson BE, Kris MG, Berry LD, Kwiatkowski DJ, Iafrate AJ, Variella-Garcia M, et al. A multicentre effort to identify driver mutation and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). J Clin Oncol. 2013;(Suppl 31; abstract 8019).
76. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958-67.
77. Bria E, Milella M, Cuppone F, Novello S, Ceribelli A, Vaccaro V, et al. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann Oncol. 2011;22:2277-85.
78. Zeng Z, Chen HJ, Yan HH, Yang JJ, Zhang XC, Wu YL. Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in male, smoker and non-adenocarcinoma lung cancer patients with EGFR mutations. Int J Biol Markers. 2013 (Epub ahead of print).
79. Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, Inoue A, et al. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer. 2010;126:651-5.
80. Mazieres J, Rouquette I, Lepage B, Milia J, Brouchet L, Gubert N, et al. Specificities of lung adenocarcinoma in women who have never smoked. J Thorac Oncol. 2013;8:923-9.
81. Traynor AM, Schiller JH, Stabile LP, Kolesar JM, Eickhoff JC, Dacic S, et al. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer. 2009;64:51-9.
82. Mazieres J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31:1997-2003.
83. Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012;18:4910-8.
84. Dogan S, Shen R, Ang DC, Johnson ML, D'Angelo SP, Paik PK, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012;18:6169-77.
85. Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29:3574-9.
86. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29:2046-51.
87. Cardarella S, Ogino A, Nishino M, Buthaney M, Shen J, Lydon C, et al. Clinical, pathological and biological features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013;19:4532-40.
88. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385-94.
89. Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist. 2013;18:865-75.
90. Micheli A, Ciampichini R, Oberaigner W, Ciccolallo L, de Vries E, Izarzugaza I, et al. The advantage of women in cancer survival: an analysis of EUROCARE-4 data. Eur J Cancer. 2009;45:1017-27.
91. Cantos B, Majem M, Garrido P, Isla D, Garrido P, Felip E, et al. Menstrual status and lung cancer in female patients from the Spanish WORLD07 database. J Clin Oncol. 2012;(Suppl 30; abstract e12012).
92. Wisnivesky JP, Halm EA. Sex differences in lung cancer survival: do tumors behave differently in elderly women? J Clin Oncol. 2007;25:1705-12. (Pubitemid 46797951)
93. Peters S, Dafni U, Bubendorf L, O'Byrne KJ, Wrona A, Dooms C, et al. The European Thoracic Oncology Platform (ETOP) Lungscape project: a way to bridge NSCLC to molecular characteristics and clinical data. J Clin Oncol. 2013;(Suppl 31; abstract 7514).
94. Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP, et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol. 2006;1:441-6. (Pubitemid 47181421)
95. Wakelee HA, Dahlberg SE, Brahmer JR, Schiller JH, Perry MC, Langer CJ, et al. Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. Lung Cancer. 2012;76:410-5.
96. Chirlaque MD, Salmeron D, Ardanaz E, Galceran J, Martinez R, Marcos-Gragera R, et al. Cancer survival in Spain: estimate for nine major cancers. Ann Oncol. 2010;21(suppl 3):iii21-9.
97. Isla D, Felip E, Garrido P, Rosell R, Camps C, Viñolas N, et al. Sex differences in non-small cell lung cancer (NSCLC) patients (p) participating in Spanish Lung Cancer Group (SLCG) trials. J Clin Oncol 2007;(Suppl 25(18S); abstract 7679).
98. Wheatley-Price P, Blackhall F, Lee SM, Ma C, Ashcroft L, Jitlal M, et al. The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Ann Oncol. 2010;21:2023-8.
99. Nakamura H, Ando K, Shinmyo T, Morita K, Mochizuki A, Kurimoto N, et al. Female gender is an independent prognostic factor in non-small-cell lung cancer: a meta-analysis. Ann Thorac Cardiovasc Surg. 2011;17:469-80.
100. Janjigian YY, Mcdonnell K, Kris MG, Shen CS, Sima CS, Bach PB, et al. Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer. 2010;116:670-5.
101. Paik PK, Johnson ML, D'Angelo SP, Sima CS, Ang D, Dogan S, et al. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Cancer. 2012;118:5840-7.